A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye
- PMID: 27929721
- PMCID: PMC5333559
- DOI: 10.1089/jop.2016.0086
A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye
Abstract
Purpose: To investigate the efficacy of 0.1%, 0.15%, and 0.3% sodium hyaluronate (SH) artificial tears compared with 0.05% cyclosporine (CS) ophthalmic solution for the treatment of dry eye.
Methods: One hundred seventy-six patients were recruited and randomized to receive of 0.1%, 0.15%, and 0.3% SH and 0.05% CS. There was a primary end point which is the changes in the fluorescein corneal staining (FCS) score to determine noninferiority of 0.1%, 0.15%, and 0.3% SH. Secondary objective end points were lissamine green conjunctival staining (LGCS) scores, Schirmer test, and tear film break-up time (TBUT). Secondary subjective end point was ocular surface disease index (OSDI) score. These were evaluated before treatment and 6 and 12 weeks after start of treatment.
Results: In the primary analysis, the mean change from baseline in FCS scores verified noninferiority of 0.1% and 0.15% SH to 0.05% CS and also indicated significant improvement of all groups (P < 0.05). Values for TBUT, LGCS scores, and OSDI scores showed significant improvements in all groups (P < 0.05), although no significant intergroup difference was shown. However, Schirmer test scores in the 0.15% SH group showed a significant tendency for better improvement at week 12 compared with the other groups (P < 0.05). No serious adverse events were observed.
Conclusions: Administration of 0.1%, 0.15%, and 0.3% SH was effective in improving both the objective signs and subjective symptoms of dry eye. Those findings, in addition to the well-tolerated profile of 0.1%, 0.15%, and 0.3% SH, show that it is effective therapeutic method for dry eye.
Keywords: 0.05% cyclosporine; 0.1% sodium hyaluronate; 0.15% sodium hyaluronate; 0.3% sodium hyaluronate; dry eye syndrome.
Conflict of interest statement
No competing financial interests exist.
Figures
References
-
- Johnson M.E., and Murphy P.J. Changes in the tear film and ocular surface from dry eye syndrome. Prog. Retin. Eye Res. 23:449–474, 2004 - PubMed
-
- International Dry Eye WorkShop Study Group. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul. Surf. 5:75–92, 2007 - PubMed
-
- Yeh S., Song X.J., Farley W., et al. . Apoptosis of ocular surface cells in experimentally induced dry eye. Invest. Ophthalmol. Vis. Sci. 44:124–129, 2003 - PubMed
-
- Management and therapy of dry eye disease: report of the management and therapy Subcommittee of the International Dry Eye Work Shop. Ocul. Surf. 5:163–178, 2007 - PubMed
-
- Babić G.S., Zlatanović G., Jocić J.D., et al. . Therapeutical approach to dry eye syndrome. Med. Pregl. 63:793–800, 2010 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical